TD Waterhouse Canada Inc. Makes New Investment in Definium Therapeutics, Inc. $DFTX

TD Waterhouse Canada Inc. purchased a new stake in shares of Definium Therapeutics, Inc. (NASDAQ:DFTX) in the second quarter, HoldingsChannel reports. The institutional investor purchased 36,694 shares of the company’s stock, valued at approximately $1,592,000.

Several other hedge funds also recently modified their holdings of the company. Nykredit A S acquired a new stake in shares of Definium Therapeutics in the second quarter valued at $45,000. Cerity Partners LLC raised its position in Definium Therapeutics by 2.4% in the second quarter. Cerity Partners LLC now owns 49,650 shares of the company’s stock worth $322,000 after acquiring an additional 1,165 shares in the last quarter. Creative Planning lifted its holdings in Definium Therapeutics by 2.6% in the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock valued at $429,000 after acquiring an additional 1,655 shares during the last quarter. Russell Investments Group Ltd. boosted its position in shares of Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after purchasing an additional 2,003 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV grew its stake in shares of Definium Therapeutics by 10.5% in the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock worth $259,000 after purchasing an additional 2,079 shares during the last quarter. 27.91% of the stock is currently owned by institutional investors and hedge funds.

Definium Therapeutics Price Performance

DFTX opened at $38.23 on Wednesday. The stock has a fifty day moving average of $43.35 and a 200-day moving average of $29.88. The firm has a market capitalization of $5.14 billion, a P/E ratio of -11.15 and a beta of 2.23. Definium Therapeutics, Inc. has a 12-month low of $8.77 and a 12-month high of $49.70. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). Equities analysts forecast that Definium Therapeutics, Inc. will post -3.02 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Robert Barrow sold 29,208 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $1,315,236.24. Following the transaction, the chief executive officer directly owned 1,098,246 shares of the company’s stock, valued at approximately $49,454,017.38. The trade was a 2.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Mark Sullivan sold 13,008 shares of the company’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $585,750.24. Following the completion of the transaction, the insider directly owned 320,571 shares in the company, valued at $14,435,312.13. This trade represents a 3.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 67,119 shares of company stock worth $2,887,496. Insiders own 2.40% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on DFTX shares. Leerink Partners set a $52.00 price objective on Definium Therapeutics and gave the stock an “outperform” rating in a research note on Monday, June 22nd. JonesTrading lifted their price target on Definium Therapeutics from $74.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. Needham & Company LLC boosted their price objective on Definium Therapeutics from $50.00 to $66.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Wall Street Zen lowered shares of Definium Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Finally, Robert W. Baird raised their target price on shares of Definium Therapeutics from $57.00 to $75.00 and gave the stock an “outperform” rating in a report on Thursday, August 13th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $63.00.

Definium Therapeutics Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.